387 related articles for article (PubMed ID: 27120807)
1. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer.
Passardi A; Scarpi E; Cavanna L; Dall'Agata M; Tassinari D; Leo S; Bernardini I; Gelsomino F; Tamberi S; Brandes AA; Tenti E; Vespignani R; Frassineti GL; Amadori D; De Giorgi U
Oncotarget; 2016 May; 7(22):33210-9. PubMed ID: 27120807
[TBL] [Abstract][Full Text] [Related]
2. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.
Dogan E; Bozkurt O; Sakalar T; Derin S; Inanc M; Ozkan M
J BUON; 2019; 24(5):1861-1869. PubMed ID: 31786848
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
Artaç M; Uysal M; Karaağaç M; Korkmaz L; Er Z; Güler T; Börüban MC; Bozcuk H
J Gastrointest Cancer; 2017 Jun; 48(2):176-180. PubMed ID: 27714653
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A; Azzali I; Bittoni A; Marisi G; Rebuzzi F; Molinari C; Bartolini G; Matteucci L; Sullo FG; Debonis SA; Gallio C; Monti M; Valgiusti M; Muratore M; Rapposelli IG; Ulivi P; Frassineti GL
Ther Adv Med Oncol; 2023; 15():17588359231212184. PubMed ID: 38107830
[TBL] [Abstract][Full Text] [Related]
5. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer.
Cruz-Ramos M; Del Puerto-Nevado L; Zheng B; López-Bajo R; Cebrian A; Rodríguez-Remirez M; García-García L; Solanes-Casado S; García-Foncillas J
J Geriatr Oncol; 2019 Sep; 10(5):742-748. PubMed ID: 30327283
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
Passardi A; Nanni O; Tassinari D; Turci D; Cavanna L; Fontana A; Ruscelli S; Mucciarini C; Lorusso V; Ragazzini A; Frassineti GL; Amadori D
Ann Oncol; 2015 Jun; 26(6):1201-1207. PubMed ID: 25735317
[TBL] [Abstract][Full Text] [Related]
8. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Cremolini C; Loupakis F; Antoniotti C; Lonardi S; Masi G; Salvatore L; Cortesi E; Tomasello G; Spadi R; Zaniboni A; Tonini G; Barone C; Vitello S; Longarini R; Bonetti A; D'Amico M; Di Donato S; Granetto C; Boni L; Falcone A
Ann Oncol; 2015 Jun; 26(6):1188-1194. PubMed ID: 25712456
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Dell'Aquila E; Cremolini C; Zeppola T; Lonardi S; Bergamo F; Masi G; Stellato M; Marmorino F; Schirripa M; Urbano F; Ronzoni M; Tomasello G; Zaniboni A; Racca P; Buonadonna A; Allegrini G; Fea E; Di Donato S; Chiara S; Tonini G; Tomcikova D; Boni L; Falcone A; Santini D
Ann Oncol; 2018 Apr; 29(4):924-930. PubMed ID: 29324972
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy.
Yang J; Xu H; Guo X; Zhang J; Ye X; Yang Y; Ma X
Sci Rep; 2018 Feb; 8(1):3044. PubMed ID: 29445100
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.
Jia W; Yuan L; Ni H; Xu B; Zhao P
Technol Cancer Res Treat; 2021; 20():15330338211034291. PubMed ID: 34308689
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).
Farolfi A; Petrone M; Scarpi E; Gallà V; Greco F; Casanova C; Longo L; Cormio G; Orditura M; Bologna A; Zavallone L; Ventriglia J; Franzese E; Loizzi V; Giardina D; Pigozzi E; Cioffi R; Pignata S; Giorda G; De Giorgi U
Target Oncol; 2018 Aug; 13(4):469-479. PubMed ID: 29948780
[TBL] [Abstract][Full Text] [Related]
16. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.
He W; Yin C; Guo G; Jiang C; Wang F; Qiu H; Chen X; Rong R; Zhang B; Xia L
Med Oncol; 2013 Mar; 30(1):439. PubMed ID: 23307251
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
18. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
[TBL] [Abstract][Full Text] [Related]
19. Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.
Passardi A; Scarpi E; Gelsomino F; Palladino MA; Casadei Gardini A; Turci D; Chiuri VE; Mucciarini C; Tassinari D; Ragazzini A; Frassineti GL; Valgiusti M; Ulivi P; Amadori D
Sci Rep; 2017 Sep; 7(1):10426. PubMed ID: 28874797
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer.
Kim JH; Lee JY; Kim HK; Lee JW; Jung SG; Jung K; Kim SE; Moon W; Park MI; Park SJ
World J Gastroenterol; 2017 Jan; 23(3):505-515. PubMed ID: 28210087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]